ULK3 regulates cytokinetic abscission by phosphorylating ESCRT-III proteins

  1. Anna Caballe
  2. Dawn M Wenzel
  3. Monica Agromayor
  4. Steven L Alam
  5. Jack J Skalicky
  6. Magdalena Kloc
  7. Jeremy G Carlton
  8. Leticia Labrador
  9. Wesley I Sundquist
  10. Juan Martin-Serrano  Is a corresponding author
  1. King's College London School of Medicine, United Kingdom
  2. University of Utah School of Medicine, United States

Abstract

The Endosomal Sorting Complexes Required for Transport (ESCRT) machinery mediates the physical separation between daughter cells during cytokinetic abscission. This process is regulated by the abscission checkpoint, a genome protection mechanism that relies on Aurora B and the ESCRT-III subunit CHMP4C to delay abscission in response to chromosome missegregation. Here we show that Unc-51-like kinase 3 (ULK3) phosphorylates and binds ESCRT-III subunits via tandem MIT domains and thereby delays abscission in response to lagging chromosomes, nuclear pore defects and tension forces at the midbody. Our structural and biochemical studies reveal an unusually tight interaction between ULK3 and IST1, an ESCRT-III subunit required for abscission. We also demonstrate that IST1 phosphorylation by ULK3 is an essential signal required to sustain the abscission checkpoint and that ULK3 and CHMP4C are functionally linked components of the timer that controls abscission in multiple physiological situations.

Article and author information

Author details

  1. Anna Caballe

    Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom
    Competing interests
    No competing interests declared.
  2. Dawn M Wenzel

    Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States
    Competing interests
    No competing interests declared.
  3. Monica Agromayor

    Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom
    Competing interests
    No competing interests declared.
  4. Steven L Alam

    Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States
    Competing interests
    No competing interests declared.
  5. Jack J Skalicky

    Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States
    Competing interests
    No competing interests declared.
  6. Magdalena Kloc

    Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom
    Competing interests
    No competing interests declared.
  7. Jeremy G Carlton

    Division of Cancer Studies, King's College London School of Medicine, London, United Kingdom
    Competing interests
    No competing interests declared.
  8. Leticia Labrador

    Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom
    Competing interests
    No competing interests declared.
  9. Wesley I Sundquist

    Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, United States
    Competing interests
    Wesley I Sundquist, Reviewing editor, eLife.
  10. Juan Martin-Serrano

    Department of Infectious Diseases, King's College London School of Medicine, London, United Kingdom
    For correspondence
    juan.martin_serrano@kcl.ac.uk
    Competing interests
    No competing interests declared.

Copyright

© 2015, Caballe et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,982
    views
  • 1,019
    downloads
  • 87
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anna Caballe
  2. Dawn M Wenzel
  3. Monica Agromayor
  4. Steven L Alam
  5. Jack J Skalicky
  6. Magdalena Kloc
  7. Jeremy G Carlton
  8. Leticia Labrador
  9. Wesley I Sundquist
  10. Juan Martin-Serrano
(2015)
ULK3 regulates cytokinetic abscission by phosphorylating ESCRT-III proteins
eLife 4:e06547.
https://doi.org/10.7554/eLife.06547

Share this article

https://doi.org/10.7554/eLife.06547

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Sasha L Evans, Bethany A Haynes ... Rivka L Isaacson
    Insight

    Nature has inspired the design of improved inhibitors for cancer-causing proteins.

    1. Biochemistry and Chemical Biology
    Gabriella O Estevam, Edmond Linossi ... James S Fraser
    Research Article

    Mutations in the kinase and juxtamembrane domains of the MET Receptor Tyrosine Kinase are responsible for oncogenesis in various cancers and can drive resistance to MET-directed treatments. Determining the most effective inhibitor for each mutational profile is a major challenge for MET-driven cancer treatment in precision medicine. Here, we used a deep mutational scan (DMS) of ~5764 MET kinase domain variants to profile the growth of each mutation against a panel of 11 inhibitors that are reported to target the MET kinase domain. We validate previously identified resistance mutations, pinpoint common resistance sites across type I, type II, and type I ½ inhibitors, unveil unique resistance and sensitizing mutations for each inhibitor, and verify non-cross-resistant sensitivities for type I and type II inhibitor pairs. We augment a protein language model with biophysical and chemical features to improve the predictive performance for inhibitor-treated datasets. Together, our study demonstrates a pooled experimental pipeline for identifying resistance mutations, provides a reference dictionary for mutations that are sensitized to specific therapies, and offers insights for future drug development.